<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04405245</url>
  </required_header>
  <id_info>
    <org_study_id>AKB-9778-CI-OS-2001</org_study_id>
    <nct_id>NCT04405245</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma</brief_title>
  <official_title>Phase 2 Multi-Center, Double-Masked, Randomized, 28-Day Study to Assess the Efficacy, Safety and Tolerability of Single or Twice Daily Doses of AKB-9778 Ophthalmic Solution as an Adjunct to Latanoprost in Patients With Ocular Hypertension (OHT) or Open Angle Glaucoma (OAG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerpio Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerpio Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, double masked, randomized, multi-center, parallel-group, 28-day study&#xD;
      assessing the safety, tolerability and ocular hypotensive efficacy of AKB-9778 Ophthalmic&#xD;
      Solution 4.0% administered once (AM) or twice (AM &amp; PM) daily when used as an adjunctive&#xD;
      therapy to latanoprost ophthalmic solution 0.005% once daily (PM) in subjects with elevated&#xD;
      IOP due to OAG or OHT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2020</start_date>
  <completion_date type="Actual">November 5, 2020</completion_date>
  <primary_completion_date type="Actual">November 5, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>Intraocular pressure in mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>AKB-9778 QD + Latanoprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• AKB-9778 QD (AM) and placebo for AKB-9778 ophthalmic solution QD (PM) plus latanoprost QD (PM) for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AKB-9778 BID + Latanoprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• AKB-9778 BID (AM &amp; PM) plus latanoprost QD (PM) for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID + Latanoprost</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>• Placebo for AKB-9778 ophthalmic solution BID (AM &amp; PM) plus latanoprost QD (PM) for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost ophthalmic solution</intervention_name>
    <description>Latanoprost opthalmic solution to be dosed once daily</description>
    <arm_group_label>AKB-9778 BID + Latanoprost</arm_group_label>
    <arm_group_label>AKB-9778 QD + Latanoprost</arm_group_label>
    <arm_group_label>Placebo BID + Latanoprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AKB-9778</intervention_name>
    <description>AKB-9778 opthalmic solution</description>
    <arm_group_label>AKB-9778 BID + Latanoprost</arm_group_label>
    <arm_group_label>AKB-9778 QD + Latanoprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo for AKB-9778 opthalmic solution</description>
    <arm_group_label>Placebo BID + Latanoprost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of OAG or OHT in each eye (OAG in one eye and OHT in the fellow eye is&#xD;
             acceptable)&#xD;
&#xD;
          -  Must be receiving treatment with a stable regimen of topical prostaglandin eyedrop for&#xD;
             a minimum of 2 weeks prior to the Screening Visit; may be taking one additional IOP&#xD;
             lowering eyedrop&#xD;
&#xD;
          -  IOP of ≥ 18 mmHg and ≤ 27 mmHg in one eye at Screening visit&#xD;
&#xD;
          -  Following 4 week washout period, IOP ≥ 24 mmHg and &lt; 36 mmHg at 08:00 hour and IOP ≥&#xD;
             22 mmHg and &lt; 36 mmHg in both eyes at 10:00, 12:00 and 16:00 hours.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant ocular disease which might interfere with interpretation of the&#xD;
             study efficacy endpoints or with safety assessments&#xD;
&#xD;
          -  Pseudoexfoliation or pigment dispersion component glaucoma&#xD;
&#xD;
          -  History of angle closure glaucoma, or narrow angles or with evidence of peripheral&#xD;
             anterior synechiae (PAS) ≥ 180 degrees by gonioscopy within 6 months prior to&#xD;
             Screening&#xD;
&#xD;
          -  Intraocular pressure ≥ 36 mmHg&#xD;
&#xD;
          -  Cup/disc ratio of &gt; 0.8 in either eye&#xD;
&#xD;
          -  Severe visual field defect or significant defect (sensitivity of ≤ 10dB) within 10&#xD;
             degrees of fixation in either eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>United Medical Research Institute</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Valley Eye Medical Group</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Eye Associates</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shettle Eye Research</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clayton Eye Clinical Research, LLC</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Research Associates</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kannarr Eye Care</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart of America Eye Care, P.A.</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekwani Vision Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Valley Eye Medical Group</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye, Ear, Nose &amp; Throat Assoc. (CEENTA)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James D. Branch, MD Ophthalmology</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Eye</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abrams Eye Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mark J. Weiss, MD, Inc.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; Christie and Assoc</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Specialists</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Total Eye Care</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advancing Vision Research</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texan Eye / Keystone Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 23, 2020</study_first_submitted>
  <study_first_submitted_qc>May 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

